Standard BioTools Inc. (LAB)
- Previous Close
2.5600 - Open
2.5700 - Bid 2.4100 x 1800
- Ask 2.4400 x 1800
- Day's Range
2.4000 - 2.5900 - 52 Week Range
1.4600 - 3.1600 - Volume
2,327,737 - Avg. Volume
2,080,785 - Market Cap (intraday)
979.101M - Beta (5Y Monthly) 1.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9400 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.50
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
www.standardbio.com534
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LAB
Performance Overview: LAB
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LAB
Valuation Measures
Market Cap
979.10M
Enterprise Value
962.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.91
Price/Book (mrq)
--
Enterprise Value/Revenue
9.05
Enterprise Value/EBITDA
-17.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-70.21%
Return on Assets (ttm)
-11.05%
Return on Equity (ttm)
-37.99%
Revenue (ttm)
106.34M
Net Income Avi to Common (ttm)
-74.66M
Diluted EPS (ttm)
-0.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
28.45M
Total Debt/Equity (mrq)
118.03%
Levered Free Cash Flow (ttm)
-8.5M